Systemic Therapy for Psoriasis

Melvin Lee, MD; Robert E. Kalb, MD


Dermatology Nursing. 2008;20(2):105-111. 

In This Article

Cyclosporine (Neoral®)

Cyclosporine works by inhibiting T-lymphocyte transcription of IL-2. The long-term use of cyclosporine can be limited by the two major side effects of renal toxicity and hypertension (Grossman, Chevret, Abi-Rached, Blanchet, & Dubertret, 1996; Mrowietz et al., 1995; Lowe, Wieder, & Rosenbach, 1996; Powles et al., 1998). More recently it has been used in a short-term approach via intermittent 3 to 4 month intervals, either to obtain a quick response before transitioning to another agent, or to control a flare in a patient on stable systemic therapy (Finzi, 1996; Ho et al., 2001). Dosing is usually started at 4 to 5 mg/kg/d and then tapered as clearance is achieved.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.